Clinical trials: Oral Anticoagulants
Non-valvular Atrial Fibrillation
Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment
To assess the safety and pharmacokinetics of DU-176b administered to non-valvular atrial fibrillation patients with severe renal impairment, compared with DU-176b administered to non-valvular atrial fibrillation (NVAF) patients…
- Trial name
- NCT01857622
- Testing
- DU-176b 15mg, DU-176b 30mg, DU-176b 60mg
- Where
- Japan
- Volunteers
- 93 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Stroke, Systemic Embolism
NOAC Portuguese Real World Study
To determine if there is any difference in the effectiveness and safety outcomes of patients with NVAF newly treated with apixaban, dabigatran, rivaroxaban and vitamin K antagonists
- Conditions
- Stroke, Systemic Embolism, Major Bleeding
- Trial name
- NCT04808934
- Testing
- Apixaban, dabigatran, rivaroxaban
- Sponsor
- Pfizer
Atrial Fibrillation (AF)
A Pharmacist-Led Education Program to Improve Adherence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation
Atrial fibrillation (irregular heartbeat) increases the risk of stroke, and patients are commonly treated with direct oral anticoagulants (DOACs).
- Trial name
- PharmAD-AF (NCT07159399)
- Testing
- Pharmacist-led patient education, Usual Care
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- National Taiwan University
Blood Loss, Surgical, Coagulation Disorder
Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
The goal of this clinical trial is to learn if reltodecacog alfa (VMX-C001) works to to allow blood clotting control in participants who take FXa Direct Oral Anticoagulants (DOACs) during surgery or other invasive procedures that…
- Trial name
- EQUILIBRIX-S (NCT07288489)
- Testing
- Reltodecacog alfa, Usual Pharmacological Care
- Where
- 77 sites in United States, Australia and 16 more
- Volunteers
- 800 people
- Sponsor
- VarmX B.V.
Healthy
PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers
This study aims to evaluate the effects of combination therapy of tegoprazan and novel oral anticoagulants (NOACs) on the pharmacokinetic and pharmacodynamic properties of NOACs in healthy adults.
- Trial name
- NCT05723510
- Testing
- Tegoprazan 50mg, Edoxaban 60mg, Apixaban 5mg
- Where
- South Korea
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Therapeutic Drug Monitoring
The Association Between Non-vitamin K Antagonist Oral Anticoagulant Therapy and Acute Stroke Severity and Post Stroke Short-term and Long-term Outcomes.
Non-vitamin K antagonist oral anticoagulant (NOAC) is the first line therapy to prevent thromboembolism in atrial fibrillation (AF) patients.
- Trial name
- NCT05283174
- Testing
- Blood sampling to test drug level
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- National Taiwan University Hospital
Atrial Fibrillation, Stroke
Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
This prospective, randomized, active-controlled, parallel arm study compares the safety and financial benefits of arterial thromboembolism prophylaxis with Warfarin vs.
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Trial name
- NEW-AF (NCT03702582)
- Testing
- Rivaroxaban, Warfarin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Drug-Related Side Effects and Adverse Reactions, Treatment Failure
DOAC ADRs Retrospective Study on Genetic Variations
The purpose of this study is to see if the participant's genetic profile and clinical factors (age, drug dose, etc.) affect drug outcomes (i.e.
- Trial name
- DARES1 (NCT04580589)
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Cipherome, Inc.
Ischemic Stroke, Atrial Fibrillation
TIMING of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation
This study will compare early with late start of treatment with Non-vitamin K oral anticoagulation (NOAC) in adult patients with acute ischemic stroke and atrial fibrillation; it is a registry-based randomized clinical trial…
- Trial name
- NCT02961348
- Testing
- Early start of NOAC, Late start of NOAC
- Where
- 36 sites in Sweden
- Volunteers
- 888 people
- Sponsor
- Uppsala University
Anticoagulant Adverse Reaction
Precision Medicine Platform for Novel Oral Anticoagulants
The anticoagulants have been developed with new generation for FDA-approved indications including treatment and prevention of venous, pulmonary, and systemic thromboembolism.
- Trial name
- NCT04056143
- Testing
- Pharmacogenomics
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- Kaohsiung Medical University
Intracranial Hemorrhages, Intracranial Hemorrhage, Hypertensive
Start or STop Anticoagulants Randomised Trial (SoSTART)
Primary research question: For adults surviving spontaneous (non-traumatic) symptomatic intracranial haemorrhage with persistent/paroxysmal atrial fibrillation/flutter (AF), does starting full treatment dose oral anticoagulation…
- Conditions
- Intracranial Hemorrhages, Intracranial Hemorrhage, Hypertensive, Subarachnoid Hemorrhage, Subdural Hematoma
- Trial name
- SoSTART (NCT03153150)
- Testing
- Apixaban, Rivaroxaban, Edoxaban
- Where
- 67 sites in United Kingdom
- Volunteers
- 203 people
- Sponsor
- University of Edinburgh
Atrial Fibrillation, Recurrent Venous Thromboembolism
Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)
MACACOD is a clinical record in the usual clinical practice of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).
- Trial name
- MACACOD (NCT04042155)
- Testing
- dabigatran, rivaroxaban, apixaban or edoxaban
- Where
- Spain
- Volunteers
- 1,600 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Combined Pulsed-field Ablation (PFA)
Combined Pulsed-field Ablation (PFA) and Left Atrial Appendage Occlusion Using Watchman Flx or Amulet
AF ablation is an established treatment option for non-valvular atrial fibrillation (NVAF). While AF ablation helps to maintain cardiac rhythm in sinus, the stroke risk associated with AF persists after ablation.
- Trial name
- COMPAWA (NCT05560204)
- Testing
- Combined Pulsed-field Ablation (PFA) + Left Atrial Appendage Occlusion (LAAO)
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
Atrial Fibrillation
Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over
The aim of the study is to compare, in real life, the risk benefit (including both major bleeding and thrombotic events (TE) and death from any cause) associated with direct oral anticoagulants (DOA) and with anti vitamin K (VKA)…
- Trial name
- PRESAGE-ACO (NCT02286414)
- Testing
- Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban, Vitamin K antagonist: warfarin, fluindione, acenocoumarol
- Where
- France
- Volunteers
- 159 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
LVAD (Left Ventricular Assist Device) Thrombosis
DOT HeartMate 3 Study
A prospective, single-center, randomized controlled trial of the feasibility and safety of apixaban in HeartMate 3 patients.
- Trial name
- NCT04974684
- Testing
- HeartMate 3, Apixaban
- Where
- Czechia
- Volunteers
- 45 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Embolism and Thrombosis, Hemorrhage
Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants
The purpose of this study is to investigate the preventability of serious adverse drug reactions (ADRs) related to the use of direct oral anticoagulants (DOACs).
- Trial name
- ADR-OAC (NCT02720328)
- Testing
- Blood samples for DOAC measurement
- Where
- 2 sites in Belgium
- Volunteers
- 102 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke)
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion
Background: Atrial fibrillation (AF) is the most common heart rhythm disorder worldwide. Globally, there are 37.5 million people with AF.
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke), Atrial Fibrillation New Onset, Non Valvular Atrial Fibrillation
- Trial name
- BIO-AF (NCT06949319)
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Nedim Tojaga
Auricular Fibrillation, Anticoagulant Drugs
Discontinuation for Oral Anticoagulants in Patients With Atrial Fibrillation
The purpose of this study is to compare the discontinuation rates for vitamin K antagonists and for direct oral anticoagulants during their first year
- Trial name
- NCT04133545
- Where
- Argentina
- Volunteers
- 360 people
- Sponsor
- Hospital Italiano de Buenos Aires
Antithrombotic Agents
Registry of Patient With Antithrombotic Agents Admitted to an Emergency Department
Antithrombotics with antiplatelet agents, vitamin K antagonist (VKA), heparin and related substances, and new oral anticoagulants are prescribed for arterial diseases, especially in secondary prevention of embolic disease in…
- Trial name
- RATED Registry (NCT02706080)
- Testing
- emergency
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Clermont-Ferrand
Antiphospholipid Syndrome, Thrombosis
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.
- Conditions
- Antiphospholipid Syndrome, Thrombosis, Anticoagulants Causing Adverse Effects in Therapeutic Use
- Trial name
- OBSTINATE (NCT04262492)
- Testing
- Rivaroxaban
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Stéphane Zuily